结直肠腺癌组织中SPTBN1、TUFT1的表达及其临床意义-东南大学学报医学版

结直肠腺癌组织中SPTBN1、TUFT1的表达及其临床意义

单位：1. 保定市第一中心医院东院检验科, 河北保定 071000;
2. 保定市第二中心医院消化内科, 河北保定 072750

分类号：R735.3

出版年·卷·期（页码）：2025·44·第二期（229-235）

摘要：

目的:探讨βⅡ-血影蛋白(SPTBN1)、釉丛蛋白1(TUFT1)在结直肠腺癌组织中的表达及其临床意义。方法:选取本院2019年9月至2020年9月收治的83例结直肠腺癌患者,在术中收集其腺癌组织,另外选取本院同期收治的83例结直肠腺瘤患者,在术中收集其腺瘤组织。采用实时荧光定量逆转录聚合酶链反应(qRT-PCR)和免疫组化法检测SPTBN1、TUFT1表达;采用Pearson法分析结直肠腺癌组织SPTBN1mRNA与TUFT1mRNA表达的相关性;采用Kaplan-Meier曲线探讨SPTBN1、TUFT1与结直肠腺癌患者3年生存率的关系;Cox回归模型探讨结直肠腺癌患者预后的影响因素。结果:与结直肠腺瘤组织相比,结直肠腺癌组织中SPTBN1表达水平及阳性表达率降低(P＜0.05),TUFT1表达水平及阳性表达率上升(P＜0.05);SPTBN1、TUFT1的表达与淋巴结转移、肿瘤直径、TNM分期、肿瘤分化程度有关(P＜0.05)。Pearson相关性分析显示,结直肠腺癌组织中SPTBN1mRNA与TUFT1mRNA表达呈负相关(r=-0.679,P＜0.05)。对结直肠腺癌患者进行为期3年的随访,结果显示,SPTBN1在癌组织中阳性表达的患者3年生存率(73.33%,22/30)比阴性表达的患者高(28.30%,15/53)(χ²=21.048,P＜0.05);TUFT1在癌组织中阳性表达的患者3年生存率(30.77%,16/52)比阴性表达的患者低(67.74%,21/31)(χ²=16.719,P＜0.05);多因素Cox回归分析显示,淋巴结转移、肿瘤直径>5.0 cm、低分化、TNM分期为Ⅲ-Ⅳ期、SPTBN1阴性表达、TUFT1阳性表达均为结直肠腺癌患者预后的危险因素(P＜0.05)。结论:结直肠腺癌组织中SPTBN1表达水平下降,TUFT1表达水平上升,二者与临床病理特征密切相关,在一定程度上可以作为评估患者预后的重要指标。

Objective: To explore the expression and clinical significance of βⅡ-spectrin(SPTBN1) and Tuftelin-1(TUFT1) in colorectal adenocarcinoma tissues. Methods: Eighty-three patients with colorectal adenocarcinoma admitted to our hospital from September 2019 to September 2020 were selected, and their adenocarcinoma tissues were collected during surgery. In addition, 83 patients with colorectal adenoma admitted to our hospital were selected, and their adenoma tissues were collected during surgery. Real-time fluorescence quantitative PCR(qRT-PCR) and immunohistochemistry were applied to detect the expression of SPTBN1 and TUFT1. Pearson method was applied to analyze the correlation between the expression of SPTBN1mRNA and TUFT1 mRNA in colorectal adenocarcinoma tissue. Kaplan-Meier curve was used to explore the relationship between SPTBN1,TUFT1 and 3-year survival rate in patients with colorectal adenocarcinoma; Cox regression model was used to explore the factors influencing the prognosis of colorectal adenocarcinoma patients. Results: Compaired to colorectal adenoma tissues,the expression level and positive expression rate of SPTBN1 in colorectal adenocarcinoma tissues decreased(P<0.05), the expression level and positive expression rate of TUFT1 increased(P<0.05); the expression of SPTBN1 and TUFT1 were related to lymph node metastasis, tumor diameter, TNM stage, tumor differentiation degree (P<0.05). Pearson correlation analysis showed, there was a negative correlation between SPTBN1mRNA and TUFT1mRNA expression in colorectal adenocarcinoma tissues(r=-0.679, P<0.05). Through a 3-year follow-up of patients with colorectal adenocarcinoma, the results showed that the 3-year survival rate of patients with positive expression of SPTBN1 in colorectal adenocarcinoma tissues(73.33%,22/30) was higher than that of patients with negative expression(28.30%,15/53)(χ²=21.048, P<0.05); The 3-year survival rate of patients with positive expression of TUFT1 in colorectal adenocarcinoma tissues(30.77%,16/52) was lower than that of patients with negative expression(67.74%,21/31)(χ²=16.719, P<0.05); Multivariate Cox regression analysis showed that lymph node metastasis, tumor diameter>5.0 cm, low differentiation, TNM stage Ⅲ-Ⅳ, SPTBN1 negative expression, and TUFT1 positive expression were all risk factors influencing the prognosis of colorectal adenocarcinoma patients(P<0.05). Conclusion: In colorectal adenocarcinoma tissues, expression level of SPTBN1 decreases, and expression levels of TUFT1 increases,both of which are closely related to clinicopathologic features, and can be used as important indicators for evaluating prognosis to a certain extent.

参考文献：

[1] SUNG H,FERLAY J,SIEGEL R L,et al.Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2] 刘晓雪,宇传华,周薇,等.中国近30年间结直肠腺癌死亡趋势分析[J].中国癌症杂志,2018,28(3):177-183.
[3] DEKKER E,TANIS P J,VLEUGELS J L A,et al.Colorectal cancer[J].Lancet,2019,394(10207):1467-1480.
[4] TANG Y,KATURI V,DILLNER A,et al.Disruption of transforming growth factor-beta signaling in ELF beta-spectrin-deficient mice[J].Science,2003,299(5606):574-577.
[5] KATURI V,TANG Y,MARSHALL B,et al.Inactivation of ELF/TGF-beta signaling in human gastrointestinal cancer[J].Oncogene,2005,24(54):8012-8024.
[6] KITISIN K,GANESAN N,TANG Y,et al.Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation[J].Oncogene,2007,26(50):7103-7110.
[7] BAEK H J,KIM S S,DA SILVA F M,et al.Inactivation of TGF-beta signaling in lung cancer results in increased CDK4 activity that can be rescued by ELF[J].Biochem Biophys Res Commun,2006,346(4):1150-1157.
[8] LUO X,WEI J,YANG F L,et al.Exosomal IncRNA HNF1A-AS1 affects cisplatin resistance in cervical cancer cells through regulatingmicroRNA-34b/TUFT1 axis[J].Cancer Cell Int,2019,19(1):323-334.
[9] LIU W,CHEN G,SUN L,et al.TUFT1 promotes triple negativebreast cancer metastasis,stemness,and chemoresistance by up-regulating the Rac1/B-catenin pathway[J].Front Oncol,2019,9(1):617-629.
[10] DE MATTEIS M A,MORROW J S.Spectrin tethers and mesh in the biosynthetic pathway[J].J Cell Sci,2000,113(13):2331-2343.
[11] MISHRA L,CAI T,YU P,et al.Elf3 encodes a novel 200-kD beta-spectrin:role in liver development[J].Oncogene,1999,18(2):353-364.
[12] TANG Y,KATURI V,IQBAL S,et al.ELF a beta-spectrin is a neuronal precursor cell marker in developing mammalian brain; structure and organization of the elf/beta-G spectrin gene[J].Oncogene,2002,21(34):5255-5267.
[13] LIN L,AMIN R,GALLICANO G I,et al.The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling[J].Oncogene,2009,28(7):961-972.
[14] LIN L,YAO Z,BHUVANESHWAR K,et al.Transcriptional regulation of STAT3 by SPTBN1 and SMAD3 in HCC through cAMP-response element-binding proteins ATF3 and CREB2[J].Carcinogenesis,2014,35(11):2393-2403.
[15] ZHI X,LIN L,YANG S,et al.βⅡ-Spectrin(SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin[J].Hepatology,2015,61(2):598-612.
[16] 袁孔现,王继年.TUFT1真核表达质粒的构建及其功能研究[J].皖西学院学报,2017,33(2):71-73.
[17] SHILO D,COHEN G,BLUMENFELD A,et al.Tuftelin is required for NGF-induced differentiation of PC12 cells[J].J Mol Neurosci,2019,68(1):135-143.
[18] ZHOU B,ZHAN H,TIN L,et al.TUFTl regulates metastasis of pancreatic cancer through HIF-Snail pathway induced epithelial-mesenchymal transition[J].Cancer Lett,2016,382(1):11-20.
[19] 曾玉群,李冰,窦常伟.姜黄素通过调控TUFT1/AKT信号通路抑制肝细胞癌增殖、迁移及侵袭研究[J].新中医,2020,52(11):6-10.
[20] DOU C,ZHOU Z,XU Q,et al.Hypoxia-induced TUFTl promotesthe growth and metastasis of hepatocellular carcinoma by activa-ting the Ca²⁺/PI3K/AKT pathway[J].Oncogene,2019,38(8):1239-1244.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录